Cytotoxic T lymphocytes after oral immunization with attenuated vaccine strains of Salmonella typhi in humans.
Not only viruses, but certain parasites and bacteria as well, can elicit CTL involved in mediating protection. It has been surmised that CTL able to lyse Salmonella typhi-infected cells are likely to be important in protecting against S. typhi, an intracellular bacterial infection, but heretofore this has not been demonstrated. Consequently, the presence of CTL activity against S. typhi-infected cells was investigated in human volunteers immunized with attenuated vaccine strains of S. typhi. Oral immunization with S. typhi strain CVD 908 elicited circulating CTL effector cells capable of killing S. typhi-infected autologous EBV-transformed cells. CTL activity was observed after 6 to 8 days of in vitro expansion in the presence of S. typhi-infected autologous EBV-transformed cells. Maximum CTL activity was observed 29 days after immunization. Depletion of CD8+ T cells eliminated or markedly reduced the CTL activity, while depletion of CD4+ T cells did not affect CTL responses. CTL activity was blocked by mAbs to human class I MHC Ags, but not by mAbs to class II MHC Ags. This first demonstration that oral immunization of volunteers with attenuated S. typhi elicits CD8+ T cell, MHC class I-restricted, CTL responses raises the possibility that CTL activity might play a significant role in protection during typhoid fever. It also encourages the future use of such attenuated strains as liver vector vaccines to stimulate specific CTL against relevant foreign Ags.
Sztein
M B
MB
Department of Pediatrics, University of Maryland School of Medicine, Baltimore 21201, USA.
Tanner
M K
MK
Polotsky
Y
Y
Orenstein
J M
JM
Levine
M M
MM
D000284:Administration, Oral; D001428:Bacterial Vaccines / Q000008:administration & dosage / Q000276:immunology*; D002472:Cell Transformation, Viral; D002478:Cells, Cultured; D004854:Herpesvirus 4, Human; D006801:Humans; D008213:Lymphocyte Activation / Q000276:immunology; D008285:Major Histocompatibility Complex / Q000235:genetics; D012485:Salmonella typhi / Q000276:immunology*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D014613:Vaccines, Attenuated / Q000008:administration & dosage / Q000276:immunology*
D001428:Bacterial Vaccines; D014613:Vaccines, Attenuated